GSK Shoulder-To-Shoulder With CureVac Over COVID-19 Vaccine U-Turn
Focus On Second-Generation After EMA Filing Withdrawal
The UK major is delighted with the German biotech's decision to throw in the regulatory towel with CVnCoV and concentrate on the firms' collaboration to development a second-generation COVID-19 vaccine. However, GSK is insisting that the partners look at both modified as well as unmodified mRNA approaches, a significant change of strategy for CureVac.
You may also be interested in...
CureVac Converts To Modified mRNA And Stock Soars
CureVac, formerly a cheerleader of the unmodified mRNA approach, is embracing the modified version for its vaccine portfolio, a move that has gone down well with the investment community.
Watch Out Pfizer, Moderna - India’s First mRNA Vaccine Is Here
With India’s first and the world’s third mRNA vaccine, Gennova plans to provide access to its COVID-19 vaccine to those deprived of doses from Pfizer and Moderna. HDT Bio Corp’s suit in the US is not seen impacting marketing plans in India, COO tells Scrip
Gaming Industry Entrepreneur Backs Ethris To Be Germany’s Next mRNA Pioneer
An online gaming entrepreneur is injecting new cash and strategic thinking into biotech Ethris – with the goal of making it a ‘gamechanger’ in inhaleable mRNA.